Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: A novel clinical biomarker

Damien J. Lapar, Marie D. Burdick, Abbas Emaminia, David A. Harris, Brett A. Strieter, Ling Liu, Mark Robbins, Irving L. Kron, Robert M. Strieter, Christine L. Lau

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Development of bronchiolitis obliterans syndrome (BOS) after lung transplantation confers increased patient morbidity and mortality. Fibrocytes are circulating bone marrowderived mesenchymal cell progenitors that influence tissue repair and fibrosis. Fibrocytes have been implicated in chronic pulmonary inflammatory processes. We investigated the correlation of circulating fibrocyte number with BOS development in lung transplant patients. Methods: We prospectively quantified circulating fibrocyte levels among lung transplant patients. Patients were stratified according to the development of BOS as indicated by predicted forced expiratory volume in 1 second. Fibrocyte activity was analyzed by flow cytometry (cluster of differentiation 45 +, collagen 1+) in a blinded manner related to clinical presentation. Results: Thirty-nine patients (61.5% men) underwent double (33.3%), left (25.6%), or right (41.0%) lung transplantation. Average patient age was similar between BOS and non-BOS patients (58.3 ± 3.9 vs 60.3 ± 2.0 years, p = 0.67). Chronic obstructive lung disease was the most common indication for lung transplantation (41.0%). Median forced expiratory volume in 1 second was lower among BOS patients compared with non-BOS patients (1.08 vs. 2.18 L/s, p = 0.001). Importantly, circulating fibrocyte numbers were increased in BOS patients compared with non-BOS patients (8.91 vs 2.96 × 105 cells/mL, p = 0.03) by flow cytometry and were incrementally increased with advancing BOS stage (p = 0.02). Conclusions: Increased circulating fibrocyte levels correlate with the development of BOS after lung transplantation and positively correlate with advancing BOS stage. Quantification of circulating fibrocytes could serve as a novel biomarker and possible therapeutic target for BOS development in lung transplant patients.

Original languageEnglish (US)
Pages (from-to)470-477
Number of pages8
JournalAnnals of Thoracic Surgery
Volume92
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Bronchiolitis Obliterans
Lung Transplantation
Biomarkers
Lung
Forced Expiratory Volume
Transplants
Flow Cytometry
Mesenchymal Stromal Cells
Chronic Obstructive Pulmonary Disease

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation : A novel clinical biomarker. / Lapar, Damien J.; Burdick, Marie D.; Emaminia, Abbas; Harris, David A.; Strieter, Brett A.; Liu, Ling; Robbins, Mark; Kron, Irving L.; Strieter, Robert M.; Lau, Christine L.

In: Annals of Thoracic Surgery, Vol. 92, No. 2, 01.08.2011, p. 470-477.

Research output: Contribution to journalArticle

Lapar, Damien J. ; Burdick, Marie D. ; Emaminia, Abbas ; Harris, David A. ; Strieter, Brett A. ; Liu, Ling ; Robbins, Mark ; Kron, Irving L. ; Strieter, Robert M. ; Lau, Christine L. / Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation : A novel clinical biomarker. In: Annals of Thoracic Surgery. 2011 ; Vol. 92, No. 2. pp. 470-477.
@article{3743b29e87d14bf59281a884633fb1d2,
title = "Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: A novel clinical biomarker",
abstract = "Background: Development of bronchiolitis obliterans syndrome (BOS) after lung transplantation confers increased patient morbidity and mortality. Fibrocytes are circulating bone marrowderived mesenchymal cell progenitors that influence tissue repair and fibrosis. Fibrocytes have been implicated in chronic pulmonary inflammatory processes. We investigated the correlation of circulating fibrocyte number with BOS development in lung transplant patients. Methods: We prospectively quantified circulating fibrocyte levels among lung transplant patients. Patients were stratified according to the development of BOS as indicated by predicted forced expiratory volume in 1 second. Fibrocyte activity was analyzed by flow cytometry (cluster of differentiation 45 +, collagen 1+) in a blinded manner related to clinical presentation. Results: Thirty-nine patients (61.5{\%} men) underwent double (33.3{\%}), left (25.6{\%}), or right (41.0{\%}) lung transplantation. Average patient age was similar between BOS and non-BOS patients (58.3 ± 3.9 vs 60.3 ± 2.0 years, p = 0.67). Chronic obstructive lung disease was the most common indication for lung transplantation (41.0{\%}). Median forced expiratory volume in 1 second was lower among BOS patients compared with non-BOS patients (1.08 vs. 2.18 L/s, p = 0.001). Importantly, circulating fibrocyte numbers were increased in BOS patients compared with non-BOS patients (8.91 vs 2.96 × 105 cells/mL, p = 0.03) by flow cytometry and were incrementally increased with advancing BOS stage (p = 0.02). Conclusions: Increased circulating fibrocyte levels correlate with the development of BOS after lung transplantation and positively correlate with advancing BOS stage. Quantification of circulating fibrocytes could serve as a novel biomarker and possible therapeutic target for BOS development in lung transplant patients.",
author = "Lapar, {Damien J.} and Burdick, {Marie D.} and Abbas Emaminia and Harris, {David A.} and Strieter, {Brett A.} and Ling Liu and Mark Robbins and Kron, {Irving L.} and Strieter, {Robert M.} and Lau, {Christine L.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1016/j.athoracsur.2011.04.065",
language = "English (US)",
volume = "92",
pages = "470--477",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation

T2 - A novel clinical biomarker

AU - Lapar, Damien J.

AU - Burdick, Marie D.

AU - Emaminia, Abbas

AU - Harris, David A.

AU - Strieter, Brett A.

AU - Liu, Ling

AU - Robbins, Mark

AU - Kron, Irving L.

AU - Strieter, Robert M.

AU - Lau, Christine L.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background: Development of bronchiolitis obliterans syndrome (BOS) after lung transplantation confers increased patient morbidity and mortality. Fibrocytes are circulating bone marrowderived mesenchymal cell progenitors that influence tissue repair and fibrosis. Fibrocytes have been implicated in chronic pulmonary inflammatory processes. We investigated the correlation of circulating fibrocyte number with BOS development in lung transplant patients. Methods: We prospectively quantified circulating fibrocyte levels among lung transplant patients. Patients were stratified according to the development of BOS as indicated by predicted forced expiratory volume in 1 second. Fibrocyte activity was analyzed by flow cytometry (cluster of differentiation 45 +, collagen 1+) in a blinded manner related to clinical presentation. Results: Thirty-nine patients (61.5% men) underwent double (33.3%), left (25.6%), or right (41.0%) lung transplantation. Average patient age was similar between BOS and non-BOS patients (58.3 ± 3.9 vs 60.3 ± 2.0 years, p = 0.67). Chronic obstructive lung disease was the most common indication for lung transplantation (41.0%). Median forced expiratory volume in 1 second was lower among BOS patients compared with non-BOS patients (1.08 vs. 2.18 L/s, p = 0.001). Importantly, circulating fibrocyte numbers were increased in BOS patients compared with non-BOS patients (8.91 vs 2.96 × 105 cells/mL, p = 0.03) by flow cytometry and were incrementally increased with advancing BOS stage (p = 0.02). Conclusions: Increased circulating fibrocyte levels correlate with the development of BOS after lung transplantation and positively correlate with advancing BOS stage. Quantification of circulating fibrocytes could serve as a novel biomarker and possible therapeutic target for BOS development in lung transplant patients.

AB - Background: Development of bronchiolitis obliterans syndrome (BOS) after lung transplantation confers increased patient morbidity and mortality. Fibrocytes are circulating bone marrowderived mesenchymal cell progenitors that influence tissue repair and fibrosis. Fibrocytes have been implicated in chronic pulmonary inflammatory processes. We investigated the correlation of circulating fibrocyte number with BOS development in lung transplant patients. Methods: We prospectively quantified circulating fibrocyte levels among lung transplant patients. Patients were stratified according to the development of BOS as indicated by predicted forced expiratory volume in 1 second. Fibrocyte activity was analyzed by flow cytometry (cluster of differentiation 45 +, collagen 1+) in a blinded manner related to clinical presentation. Results: Thirty-nine patients (61.5% men) underwent double (33.3%), left (25.6%), or right (41.0%) lung transplantation. Average patient age was similar between BOS and non-BOS patients (58.3 ± 3.9 vs 60.3 ± 2.0 years, p = 0.67). Chronic obstructive lung disease was the most common indication for lung transplantation (41.0%). Median forced expiratory volume in 1 second was lower among BOS patients compared with non-BOS patients (1.08 vs. 2.18 L/s, p = 0.001). Importantly, circulating fibrocyte numbers were increased in BOS patients compared with non-BOS patients (8.91 vs 2.96 × 105 cells/mL, p = 0.03) by flow cytometry and were incrementally increased with advancing BOS stage (p = 0.02). Conclusions: Increased circulating fibrocyte levels correlate with the development of BOS after lung transplantation and positively correlate with advancing BOS stage. Quantification of circulating fibrocytes could serve as a novel biomarker and possible therapeutic target for BOS development in lung transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=79960960615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960960615&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2011.04.065

DO - 10.1016/j.athoracsur.2011.04.065

M3 - Article

C2 - 21801908

AN - SCOPUS:79960960615

VL - 92

SP - 470

EP - 477

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 2

ER -